IASLC-WCLC 2021 - IASLC World Conference on Lung Cancer (Virtual Meeting)
Sep 08 - Sep 14, 2021 | DenverCOUS
LARVOL is not affiliated with IASLC World Conference on Lung Cancer (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 140 abstracts linked to Trials
[VIRTUAL] Durvalumab ± Tremelimumab + Chemotherapy as First - line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
[VIRTUAL] First - line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA
[VIRTUAL] Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial
[VIRTUAL] IMpower010: Characterization of Stage IB - IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab
[VIRTUAL] A Phase II Study of Frontline Rucaparib + Nivolumab in Platinum Sensitive ES SCLC: Interim Analysis
[VIRTUAL] What Evidence Level is Enough for Approval and Reimbursement of Novel Cancer Drugs? Lessons from Lung Cancer
[VIRTUAL] Neoadjuvant Pembrolizumab for Early Stage Non - Small Cell Lung Cancer
[VIRTUAL] A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor (KCSG LU17 - 21)
[VIRTUAL] EPICAL Trial. A Phase Ib StudyCombining Anti - Epidermal Growth Factor (EGF) Vaccination With Afatinib in EGFR - Mutant Non - Small Cell Lung Cancer
[VIRTUAL] TROPION - PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors
[VIRTUAL] Phase II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Recurrent Non - Small Cell Lung Cancer
[VIRTUAL] Body Mass Index Predicts Benefit From Adding Metformin to EGFR - TKIs in Patients With Lung Adenocarcinoma: Subanalysis From an RCT
[VIRTUAL] Evaluating Circulating Tumor DNA to Predict Overall Survival Risk in Non - Squamous Non - Small Cell Lung Cancer in IMpower150
[VIRTUAL] Phase 1b Study of Pelcitoclax (APG - 1252) in Combination With Osimertinib in Patients With EGFR TKI - Resistant NSCLC
[VIRTUAL] Effects of the Immunotherapy Era on Maintenance Outcomes in Advanced Nonsquamous NSCLC: Subgroup Analysis of ECOG 5508